EmbryoGlue in IVF: Does the Extra Cost Buy a Better Chance of Birth?

EmbryoGlue promises an extra helping hand at embryo transfer—but does paying for this IVF add-on improve the chance of a live birth? A randomized trial of 865 women found a higher numerical live birth rate with the hyaluronic acid-enriched medium, yet the difference was not statistically significant. The detail that complicates the answer: the standard medium also contained hyaluronic acid.

Multicenter RCT of 865 Single Blastocyst Transfers: Live birth rate reached 51.5% in the EmbryoGlue group vs. 47.7% in standard transfer medium

No Statistically Significant Difference: Relative Risk (RR) of 1.08 (95% CI: 0.95–1.23, P = 0.261); clinical pregnancy rate (63.0% vs. 57.2%) and miscarriage rate (11.5% vs. 9.3%) also showed no statistically significant divergence

Subgroup Stratifications Show No Substantial Advantage: Patients aged 35 and older, those with prior transfer failures, and PGT-A euploid cohorts failed to show clear benefit

Control Media Nuance: Modern standard transfer media already contain low-dose hyaluronic acid (0.125 mg/mL); the trial did not demonstrate an incremental benefit from high-concentration enrichment (0.5 mg/mL) rather than absolute biological inactivity

During the final step of In Vitro Fertilization (IVF)—loading the embryo into the catheter and placing it into the uterine cavity—patients hope for every possible biological advantage. This clinical desire has driven the popularity of EmbryoGlue, a specialized transfer medium marketed to facilitate blastocyst adhesion to the endometrium.

Promoted as a clinical “add-on” for patients with prior implantation failures or limited embryo cohorts, EmbryoGlue has been widely adopted internationally.

However, findings from a multicenter randomized controlled trial (RCT) presented at the 2026 Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) and published in Human Reproduction provide rigorous perspective: while the raw live birth rate trended 3.8 percentage points higher with EmbryoGlue, the difference did not reach statistical significance.

The Biological Rationale: Hyaluronic Acid and the Implantation Niche

EmbryoGlue is not a synthetic glue or physical adhesive. Its primary active constituent is a high concentration of Hyaluronic Acid (HA, 0.5 mg/mL) combined with recombinant human albumin.

Hyaluronic acid is a naturally occurring glycosaminoglycan present within the human female reproductive tract and extracellular matrix. During the physiological window of implantation:

CD44 Receptor Binding: Both the developing blastocyst trophectoderm and the receptive endometrial luminal epithelium express CD44 cell-surface receptors, for which hyaluronic acid serves as the primary ligand.
Biochemical Cross-Talk & Viscosity: HA is hypothesized to act as a molecular bridge, promoting cell-to-cell adhesion, enhancing local paracrine signaling, and providing physical viscosity that prevents the transfer droplet from inadvertently displacing or expelling the embryo post-transfer.

While early trials and retrospective series suggested potential benefits, much of that historical literature included multi-embryo transfers, cleavage-stage embryos, or heterogeneous cohorts. High-grade evidence evaluating elective single blastocyst transfer (eSBT)—the standard of care in modern ART—remained limited.

Trial Design: Evaluating 865 Single Blastocyst Transfers

The multicenter double-blind RCT enrolled 865 women undergoing single blastocyst transfers across four academic IVF centers in China:

EmbryoGlue Cohort (n = 435): Blastocysts were incubated in high-concentration HA medium (0.5 mg/mL) for approximately 30 minutes immediately prior to transfer.
Standard Control Cohort (n = 430): Blastocysts were handled and transferred in standard commercial transfer medium containing low-concentration baseline HA (approximately 0.125 mg/mL).

The primary clinical endpoint was Live Birth Rate (LBR) per transfer. Participants and physicians were blinded; embryologists were not. These findings are reported in a conference abstract.

Primary and Secondary Reproductive Outcomes

Clinical Milestone	EmbryoGlue (n = 435)	Standard Medium (n = 430)	Absolute Difference	Relative Risk (RR) / P-value
Live Birth Rate (Primary)	51.5% (224/435)	47.7% (205/430)	+3.8%p	RR 1.08 (95% CI: 0.95–1.23), P = 0.261 (NS)
Clinical Pregnancy Rate	63.0%	57.2%	+5.8%p	RR 1.10 (95% CI: 0.99–1.23), P = 0.083 (NS)
Biochemical Pregnancy Rate	70.3%	65.1%	+5.2%p	RR 1.08 (95% CI: 0.99–1.18), P = 0.100 (NS)
Clinical Miscarriage Rate	11.5%	9.3%	+2.2%p	RR 1.24 (95% CI: 0.83–1.83), P = 0.291 (NS)

(NS = Not Statistically Significant)

While positive numerical trends were observed across biochemical and clinical pregnancy rates, these comparisons did not reach statistical significance (P > 0.05); this does not prove equivalence. Furthermore, miscarriage rates were slightly higher in the EmbryoGlue cohort (11.5% vs. 9.3%), though this difference was likewise statistically non-significant.

Subgroup Analyses: No Isolated Responder Cohort Identified

To evaluate whether specific patient demographics might derive a selective benefit from high-concentration HA enrichment, the researchers conducted pre-specified subgroup analyses:

Maternal Age: Neither younger patients (< 35 years) nor women of advanced reproductive age (>= 35 years) showed statistically significant live birth improvements.
Transfer History: Patients undergoing their first transfer and those with previous failed attempts exhibited comparable outcomes between groups.
Ploidy Status (PGT-A): Outcomes did not significantly diverge whether embryos were screened euploid blastocysts or untested.
Cycle Modality & Morphology: Neither fresh vs. frozen-thawed status nor blastocyst morphological grading altered the non-significant comparative outcome.

The Formulation Factor: HA Enrichment vs. Complete HA Absence

A key pharmacological consideration in this trial is that the comparator arm was not an HA-free medium.

The standard commercial transfer medium used in the control arm already contained a baseline concentration of hyaluronic acid (approx. 0.125 mg/mL).

Consequently, this trial evaluated high-concentration HA enrichment (0.5 mg/mL) versus low-dose baseline HA (0.125 mg/mL), rather than comparing HA to a completely devoid medium.
The low-HA comparator may have reduced the ability to detect an additional benefit; receptor saturation was not established by this trial.

Clinical Implications for IVF Add-Ons

These findings contextualize the clinical role of EmbryoGlue within modern assisted reproduction:

Reported Safety: No major maternal or neonatal complications were reported among completed pregnancies; this does not establish the absence of all risks.
Re-evaluating Routine Prescriptions: For clinics charging significant out-of-pocket add-on fees, this large-scale RCT indicates that routinely adding high-dose EmbryoGlue to elective single blastocyst transfers does not reliably improve live birth rates over modern standard media.
The Multi-Factorial Nature of Implantation: Implantation relies on embryonic chromosomal competence, synchronized endometrial receptivity, maternal vascularization, and immune tolerance. Manipulating the viscosity or HA content of the transfer catheter fluid cannot overcome underlying aneuploidy or endometrial pathology.

Conclusion

EmbryoGlue remains a biologically plausible transfer medium formulation. However, in contemporary IVF practice utilizing single blastocyst transfers and modern standard culture media, high-concentration hyaluronic acid enrichment fails to deliver a statistically significant improvement in live birth outcomes.

Evidence-based reproductive medicine requires that commercial add-ons demonstrate verifiable clinical efficacy in prospective randomized trials rather than relying solely on intuitive naming or biological theory.

Medical Source & Study Information

Presentation: European Society of Human Reproduction and Embryology (ESHRE) 42nd Annual Meeting (2026)
Journal Publication: Human Reproduction, Volume 41, Supplement 1 (Abstract L26/O-310)
Study Title: The efficacy of hyaluronic acid enriched embryo transfer medium in women undergoing single blastocyst transfer: a multicentre randomised controlled trial
Lead Author: H. Cai et al.
DOI: 10.1093/humrep/deag083.308

※ This article was synthesized based on the multicenter randomized controlled trial published in the Human Reproduction ESHRE Supplement (2026) alongside clinical add-on evaluation guidelines from the HFEA and ESHRE. It does not replace individualized clinical diagnosis or medical care, and specific treatment decisions should always be made in consultation with a qualified reproductive specialist.

※ The images associated with this article were generated using generative AI (ChatGPT, OpenAI) as illustrative visual references and do not depict real individuals.